Research Analysts Set Expectations for biote Corp.’s Q4 2024 Earnings (NASDAQ:BTMD)

biote Corp. (NASDAQ:BTMDFree Report) – Equities researchers at Roth Capital increased their Q4 2024 earnings per share (EPS) estimates for shares of biote in a report released on Friday, June 21st. Roth Capital analyst G. Kelly now expects that the company will post earnings per share of $0.19 for the quarter, up from their prior forecast of $0.18. The consensus estimate for biote’s current full-year earnings is $0.55 per share. Roth Capital also issued estimates for biote’s Q1 2025 earnings at $0.16 EPS, Q2 2025 earnings at $0.22 EPS, Q3 2025 earnings at $0.22 EPS, Q4 2025 earnings at $0.29 EPS and FY2025 earnings at $0.88 EPS.

Separately, Roth Mkm reiterated a “buy” rating and issued a $9.00 price objective (up previously from $8.00) on shares of biote in a research note on Wednesday, March 13th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $8.11.

View Our Latest Stock Analysis on biote

biote Trading Up 0.7 %

BTMD opened at $7.35 on Monday. biote has a 12-month low of $3.65 and a 12-month high of $8.22. The firm has a 50 day moving average of $6.14 and a two-hundred day moving average of $5.49. The firm has a market capitalization of $455.96 million, a PE ratio of 66.82 and a beta of 0.95.

biote (NASDAQ:BTMDGet Free Report) last announced its quarterly earnings data on Tuesday, May 7th. The company reported $0.23 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.05 by $0.18. The firm had revenue of $46.80 million during the quarter, compared to analysts’ expectations of $47.09 million. biote had a negative return on equity of 36.67% and a net margin of 4.30%.

Institutional Trading of biote

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Kent Lake Capital LLC lifted its position in shares of biote by 0.8% during the 3rd quarter. Kent Lake Capital LLC now owns 1,284,297 shares of the company’s stock valued at $6,576,000 after buying an additional 10,596 shares in the last quarter. SG Americas Securities LLC acquired a new stake in shares of biote in the fourth quarter valued at about $53,000. Bailard Inc. purchased a new stake in shares of biote during the fourth quarter worth about $96,000. Barclays PLC raised its position in shares of biote by 768.1% during the 3rd quarter. Barclays PLC now owns 24,490 shares of the company’s stock worth $126,000 after purchasing an additional 21,669 shares during the last quarter. Finally, SW Investment Management LLC lifted its stake in biote by 3.5% in the 4th quarter. SW Investment Management LLC now owns 675,000 shares of the company’s stock valued at $3,334,000 after buying an additional 22,651 shares in the last quarter. Institutional investors and hedge funds own 21.68% of the company’s stock.

About biote

(Get Free Report)

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.

See Also

Earnings History and Estimates for biote (NASDAQ:BTMD)

Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.